• Kayvan Mohkam, Benjamin Darnis, Zoé Schmitt, Serge Duperret, Christian Ducerf, and Jean-Yves Mabrut.
• Department of General Surgery and Liver Transplantation, Croix-Rousse University Hospital, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69317 Cedex 04, Lyon, France; Equipe Mixte de Recherche 3738, Ecole Doctorale EDISS 205, Université Claude Bernard Lyon 1, Villeurbanne, France; Ecole de Chirurgie de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
• Am. J. Surg. 2016 Aug 1; 212 (2): 321-6.

BackgroundSomatostatin may prevent the small-for-size syndrome in subjects undergoing extended hepatectomy by decreasing portal pressure.MethodsTwenty pigs underwent 70% hepatectomy (H70 group, n = 7), 90% hepatectomy (H90 group, n = 7), or sham laparotomy (control group, n = 6). Splanchnic hemodynamics was measured before and after an intraoperative infusion of somatostatin.ResultsThe portal vein flow normalized to liver weight increased in both H70 and H90 groups (from 125 ± 42 to 342 ± 82 mL/min/100g, P = .031 and from 140 ± 46 to 530 ± 241, P = .016, respectively). The hepatic venous pressure gradient (HVPG) increased in the H90 group only (from 5.5 ± 5.8 to 13 ± 4.9 mm Hg, P = .004). Somatostatin decreased portal vein flow normalized to liver weight in both H70 and H90 groups (from 408 ± 224 to 360 ± 227 mL/min/100g, P = .031 and from 560 ± 190 to 466 ± 189 mL/min/100g, P = .016), and restored a normal HVPG in the H90 group (from 14.3 ± 4.8 to 7.7 ± 6.1 mm Hg, P = .047).ConclusionsSomatostatin restores a normal HVPG in the setting of small-for-size syndrome and can be considered as an effective pharmaceutical modality of portal inflow modulation after extended hepatectomy.Copyright © 2016 Elsevier Inc. All rights reserved.

26 keywords...

hide…